Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variation in Surgical Management of Stage IV Breast Cancer: Local/Institutional and Regional Geographic Considerations.

Annals of surgical oncology·2026
Same authorSame journal

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology.

Research square·2026
Same author

Withdrawal of Guideline-Directed Medical Therapy in Heart Failure With Improved Ejection Fraction: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.

JACC. Heart failure·2026
Same author

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jul 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

William J Gradishar1, Meena S Moran2, Jame Abraham3

  • 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Journal of the National Comprehensive Cancer Network : JNCCN
|June 12, 2023
PubMed
Summary

The NCCN Guidelines for Breast Cancer offer updated systemic therapy recommendations for stage IV disease. These insights reflect the evolving treatment landscape for metastatic breast cancer, prioritizing patient survival.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K

Related Experiment Videos

Last Updated: Jul 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K

Area of Science:

  • Oncology
  • Medical Guidelines

Background:

  • The management of breast cancer is complex and continually evolving.
  • Metastatic breast cancer treatment strategies are increasingly personalized based on tumor biology and biomarkers.
  • Advances in systemic therapies offer improved survival outcomes for patients with advanced disease.

Purpose of the Study:

  • To provide an overview of recent updates to the NCCN Clinical Practice Guidelines for Breast Cancer.
  • To focus specifically on systemic therapy recommendations for patients diagnosed with stage IV (M1) metastatic breast cancer.
  • To highlight the dynamic nature of breast cancer treatment and the availability of subsequent lines of therapy.

Main Methods:

  • Review of the latest NCCN Clinical Practice Guidelines for Breast Cancer.
  • Analysis of systemic therapy recommendations for metastatic (stage IV) breast cancer.
  • Focus on updates relevant to current clinical practice and evolving treatment options.

Main Results:

  • The NCCN Guidelines for Breast Cancer provide comprehensive management strategies.
  • Recent updates focus on systemic therapies for stage IV disease.
  • Personalized therapeutic approaches considering tumor biology and biomarkers are emphasized.

Conclusions:

  • The NCCN Guidelines offer crucial updates for managing metastatic breast cancer.
  • Evolving treatment options ensure subsequent lines of therapy are available.
  • These guidelines support improved survival for patients with stage IV breast cancer.